We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanogen to Acquire SYN X Pharma

By HospiMedica staff writers
Posted on 24 Feb 2004
In a move that will provide the company with a pipeline of complementary diagnostic products, Nanogen, Inc. More...
(San Diego, CA, USA) has agreed to acquire SYN X Pharma, Inc. (Toronto, Canada) in an all-stock transaction.

SYN X is preparing to commercialize a point-of-care diagnostic product for congestive heart failure (CHF) as a result of a worldwide license to the marker NT-pro-BNP (N-terminal pro-hormone brain natriuretic peptide) from Roche Diagnostics. SYN X's test will offer stability at room temperature and quicker results. The company currently markets point-of-care diagnostic tests for myocardial infarction, infectious diseases, and drugs of abuse; and is developing a line of tests under the brand name Nexus Dx for insulin resistance and traumatic brain injury.

"The acquisition of SYN X supports Nanogen's long-term strategy to commercialize advanced diagnostics that enhance the level of medical care for the detection, diagnosis, monitoring, and treatment of disease,” said Howard Birndorf, chairman and CEO of Nanogen. The company intends to operate SYN X as a business unit and to retain the SYN X brand name and the Toronto research facility.




Related Links:
Nanogen
SYN X

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Resorbable Bovine Collagen Membrane
GenDerm
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Allevion Medical receives FDA Clearance for Vantage, introducing a fully disposable approach to minimally invasive spinal decompression (photo courtesy of Allevion Medical)

Single-Use System Enables Minimally Invasive Decompression for Lumbar Spinal Stenosis

Lumbar spinal stenosis is frequently driven by hypertrophic bone that narrows the canal and produces pain. Conventional decompression often relies on larger incisions and bulky retractors, adding time,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.